Ken Griffin’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $164M | Buy |
1,551,900
+425,213
| +38% | +$37.6M | 0.03% | 545 |
|
|
2025
Q4 | $98.4M | Buy |
1,126,687
+888,806
| +374% | +$72.7M | 0.01% | 878 |
|
|
2025
Q3 | $15.8M | Buy |
237,881
+210,680
| +775% | +$12M | ﹤0.01% | 2624 |
|
|
2025
Q2 | $1.5M | Sell |
27,201
-126,866
| -82% | -$6.09M | ﹤0.01% | 6252 |
|
|
2025
Q1 | $7.45M | Sell |
154,067
-10,079
| -6% | -$422K | ﹤0.01% | 3272 |
|
|
2024
Q4 | $6.34M | Buy |
164,146
+159,116
| +3,163% | +$6.94M | ﹤0.01% | 3591 |
|
|
2024
Q3 | $226K | Buy |
+5,030
| New | +$203K | ﹤0.01% | 9894 |
|
|
2024
Q2 | – | Sell |
-45,616
| Closed | -$1.34M | – | 15164 |
|
|
2024
Q1 | $1.32M | Sell |
45,616
-2,248
| -5% | -$61.2K | ﹤0.01% | 6357 |
|
|
2023
Q4 | $1.1M | Sell |
47,864
-2,932
| -6% | -$51.3K | ﹤0.01% | 6484 |
|
|
2023
Q3 | $847K | Sell |
50,796
-498,198
| -91% | -$9.67M | ﹤0.01% | 6923 |
|
|
2023
Q2 | $15.2M | Sell |
548,994
-615,686
| -53% | -$15.4M | ﹤0.01% | 2167 |
|
|
2023
Q1 | $26.8M | Sell |
1,164,680
-1,190,634
| -51% | -$20M | 0.01% | 1637 |
|
|
2022
Q4 | $25.7M | Buy |
2,355,314
+1,488,927
| +172% | +$12.6M | 0.01% | 1701 |
|
|
2022
Q3 | $7.3M | Buy |
866,387
+792,258
| +1,069% | +$7.5M | ﹤0.01% | 3243 |
|
|
2022
Q2 | $586K | Sell |
74,129
-112,695
| -60% | -$1.36M | ﹤0.01% | 8288 |
|
|
2022
Q1 | $4.42M | Buy |
186,824
+151,276
| +426% | +$4.26M | ﹤0.01% | 4417 |
|
|
2021
Q4 | $1.22M | Sell |
35,548
-83,156
| -70% | -$2.63M | ﹤0.01% | 7461 |
|
|
2021
Q3 | $2.1M | Sell |
118,704
-284,504
| -71% | -$12.1M | ﹤0.01% | 6229 |
|
|
2021
Q2 | $18.1M | Buy |
403,208
+204,990
| +103% | +$6.77M | ﹤0.01% | 2208 |
|
|
2021
Q1 | $5.13M | Sell |
198,218
-142,604
| -42% | -$3.61M | ﹤0.01% | 4202 |
|
|
2020
Q4 | $6.87M | Buy |
+340,822
| New | +$7.34M | ﹤0.01% | 3146 |
|
|
2020
Q2 | – | Sell |
-469,212
| Closed | -$3.31M | – | 10357 |
|
|
2020
Q1 | $3.31M | Buy |
469,212
+10,119
| +2% | +$75.8K | ﹤0.01% | 3306 |
|
|
2019
Q4 | $3.24M | Buy |
459,093
+42,838
| +10% | +$425K | ﹤0.01% | 3678 |
|
|
2019
Q3 | $5M | Buy |
416,255
+6,408
| +2% | +$80.8K | ﹤0.01% | 3112 |
|
|
2019
Q2 | $4.96M | Buy |
409,847
+46,120
| +13% | +$510K | ﹤0.01% | 3095 |
|
|
2019
Q1 | $4.57M | Buy |
363,727
+328,965
| +946% | +$2.9M | ﹤0.01% | 3130 |
|
|
2018
Q4 | $234K | Sell |
34,762
-995
| -3% | -$7.89K | ﹤0.01% | 7642 |
|
|
2018
Q3 | $368K | Sell |
35,757
-95,644
| -73% | -$823K | ﹤0.01% | 7231 |
|
|
2018
Q2 | $883K | Buy |
131,401
+82,204
| +167% | +$631K | ﹤0.01% | 5439 |
|
|
2018
Q1 | $423K | Buy |
+49,197
| New | +$927K | ﹤0.01% | 6187 |
|
Other funds holding PTGX
FCM
RI
VPM
VCM
JJ
Ken Griffin's PTGX Position: Q1 2026 in Review
Ken Griffin increased its Protagonist Therapeutics (PTGX) stake by 38% in Q1 2026, buying an estimated $37.6M and bringing the position to 1,551,900 shares worth $164M. The position accounts for 0.03% of the portfolio, ranked #545.
Ken Griffin first reported a position in PTGX in Q1 2018 and has held it in 30 quarters since. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.
- Ken Griffin held 1,551,900 shares of Protagonist Therapeutics worth $164M as of Q1 2026.
- Ken Griffin bought 425,213 Protagonist Therapeutics shares in Q1 2026, an estimated $37.6M.
- Protagonist Therapeutics made up 0.03% of Ken Griffin's portfolio in Q1 2026, its #545 holding.
- Ken Griffin first reported a position in Protagonist Therapeutics in Q1 2018 and has held it in 30 quarters since.
- 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.